As Covid-19 R&D goes into overdrive, nuts-and-bolts biopharma research is hitting the skids. How bad is it?
Typically, word that the microcap Swiss biotech Addex had delayed a key clinical trial wouldn’t garner much attention.
Today, though, it’s another early sign that clinical trial work — the basic nuts-and-bolts efforts needed to keep a biotech on track — has begun to derail on a global scale. And Addex’s reasons for the delay leave little doubt that unless you’re working on Covid-19, the biopharma world is experiencing a punishing slowdown — if not collapse — of basic trial activities.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.